sábado, 17 de octubre de 2020

Fact Sheet for Healthcare Providers: AdviseDx SARS-CoV-2 IgM | NLM

Disaster Information Management Research Center | NLM

Disaster Information and Emergency Response

10/09/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 10/9/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the AdviseDx SARS-CoV-2 IgM assay. The AdviseDx SARS-CoV-2 IgM assay is authorized for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum, serum separator tube, and plasma (dipotassium EDTA, tripotassium EDTA, lithium heparin, lithium heparin separator tube, sodium heparin). (PDF)

No hay comentarios: